Health Care • Medical/Dental Instruments
$13.15 ▲ +0.04
(+0.31%)
MKT CAP: $1.53B • VOL: 1.97M
52W L $10 52W H $21
NVCR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $655.4M | $605.2M | $509.3M |
| YoY Revenue Growth % | +8.3% | +18.8% | — |
| Gross Profit | $488.5M | $468.0M | — |
| Gross Margin % | 74.5% | 77.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$153.8M | -$170.5M | -$232.9M |
| Operating Margin % | -23.5% | -28.2% | -45.7% |
| Net Income (GAAP) | -$136.2M | -$169.0M | -$207.0M |
| EBITDA (Normalized) | -$132.5M | -$136.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.0M | -$26.4M | -$73.3M |
| Capital Expenditures (CapEx) | $26.6M | $42.9M | — |
| Free Cash Flow (FCF) | -$75.7M | -$69.2M | -$73.3M |
| FCF Margin % | -11.5% | -11.4% | -14.4% |
| Return on Invested Capital (ROIC %) | -27.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $93.5M | $163.8M | — |
| Total Debt (Short + Long Term) | $195.0M | $97.3M | — |
| Total Stockholders' Equity | $340.5M | $360.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NVCR.